9 Nov14:58 Business Charles River to buy Frontage’s bioanalysis arm for $470m The Charles River Frontage deal: a $470m cash purchase of bioanalysis and DMPK units, plus a separate $616m take-private of the rest of Frontage. Keith Howard · 9 Nov
5 Nov00:23 Business Charles River Labs beats Q3 estimates, shares fall anyway Charles River Laboratories earnings beat forecasts with $982.7m revenue and raised guidance, yet CRL shares slid on 4 November 2026. Keith Howard · 5 Nov